Omalizumab

• Study analyzing the efficacy and safety of low-dose oral immunotherapy in children with severe allergy to cow's milk treated with Omalizumab… Pending
  2023-503958-12-00 Phase II 1 country Hospital Infantil Universitario Nino Jesus
• Omalizumab's dose reduction or increase in the frequency of administration in patients who suffer from allergic severe asthma Pending
  2025-520782-48-00 Phase IV 1 country Consorci Mar Parc De Salut De Barcelona
• OmaMig Pilot Pending
  2025-522448-41-00 Phase II 1 country Oslo University Hospital HF
• Omalizumab for monotherapy treatment of patients with food allergies to plant-based foods due to sensitization to LTP and profilin Pending
  2025-524629-42-00 Phase II 1 country Fundacion Publica Andaluza Para La Investigacion De Malaga En Biomedicina Y Salu…
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 Phase IV 1 country Assistance Publique Hopitaux De Paris
• Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial) Ended
  2023-506187-14-00 Phase III/IV 1 country Bispebjerg Hospital
• BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended
  2024-514764-72-00 Phase III 6 countries Curateq Biologics Private Limited
• Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-… Ended
  2024-516783-29-00 Phase IV 2 countries Cliniques Universitaires Saint-Luc
• Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST) Ended
  2024-513581-19-00 Phase III/IV 1 country Universitair Medisch Centrum Utrecht

Showing 1–9 of 9 trials